Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Abstract

Aim: The study aims to analyze the effect of long-term incubation of ERα-positive MCF7 breast cancer cells with 4-hydroxytamoxifen (HT) on their sensitivity to tubulin polymerization inhibitor docetaxel.

Methods: The analysis of cell viability was performed by the MTT method. The expression of signaling proteins was analyzed by immunoblotting and flow cytometry. ERα activity was evaluated by gene reporter assay. To establish hormone-resistant subline MCF7, breast cancer cells were treated with 4-hydroxytamoxifen for 12 months.

Results: The developed MCF7/HT subline has lost sensitivity to 4-hydroxytamoxifen, and the resistance index was 2. Increased Akt activity (2.2-fold) and decreased ERα expression (1.5-fold) were revealed in MCF7/HT cells. The activity of the estrogen receptor α was reduced (1.5-fold) in MCF7/HT. Evaluation of class III β-tubulin expression (TUBB3), a marker associated with metastasis, revealed the following trends: higher expression of TUBB3 was detected in triple-negative breast cancer MDA-MB-231 cells compared to hormone-responsive MCF7 cells (P < 0.05). The lowest expression of TUBB3 was found in hormone-resistant MCF7/HT cells (MCF7/HT < MCF7 < MDA-MB-231, approximately 1:2:4). High TUBB3 expression strongly correlated with docetaxel resistance: IC₅₀ value of docetaxel for MDA-MB-231 cells was greater than that for MCF7 cells, whereas resistant MCF7/HT cells were the most sensitive to the drug. The accumulation of cleaved PARP (a 1.6-fold increase) and Bcl-2 downregulation (1.8-fold) were more pronounced in docetaxel-treated resistant cells (P < 0.05). The expression of cyclin D1 decreased (2.8-fold) only in resistant cells after 4 nM docetaxel treatment, while this marker was unchanged in parental MCF7 breast cancer cells.

Conclusion: Further development of taxane-based chemotherapy for hormone-resistant cancer looks highly promising, especially for cancers with low TUBB3 expression.

Keywords

Cancer / docetaxel / 4-hydroxytamoxifen / class III β-tubulin / resistance / breast cancer / estrogen receptors alpha

References

[1] Trayes KP.Breast cancer treatment.Am Fam Physician2021;104:171-8

[2] Clarke R,Sevigny CM,Sengupta S.Experimental models of endocrine responsive breast cancer: strengths, limitations, and use.Cancer Drug Resist2021;4:762-83 PMCID:PMC8442978

[3] Bai Z.Breast cancer, estrogen receptor and ligands.Arch Pharm (Weinheim)2009;342:133-49

[4] Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.Drug Discov Today2016;21:1181-8

[5] Fisher B,Brown A.Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.J Clin Oncol1983;1:227-41

[6] Jordan VC.50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?.Endocr Relat Cancer2021;28:R11-30 PMCID:PMC7780369

[7] Robertson JF.ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.Br J Cancer2001;85 Suppl 2:11-4 PMCID:PMC2375169

[8] Gaudet HM,Christensen EM.The G-protein coupled estrogen receptor, GPER: the inside and inside-out story.Mol Cell Endocrinol2015;418 Pt 3:207-19

[9] Zhang J,Jiang H.ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.Cell Death Dis2017;8:e2732 PMCID:PMC5477580

[10] Toy W,Won H.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.Nat Genet2013;45:1439-45 PMCID:PMC3903423

[11] Wang ZY.Estrogen receptor alpha-36 (ER-α36): a new player in human breast cancer.Mol Cell Endocrinol2015;418 Pt 3:193-206

[12] Cottu PH.[Systemic neoadjuvant therapy of luminal breast cancer in 2016].Bull Cancer2017;104:69-78

[13] André F,Campone M.Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.Clin Cancer Res2013;19:3693-702

[14] Fan P.New insights into acquired endocrine resistance of breast cancer.Cancer Drug Resist2019;2:198-209 PMCID:PMC6897388

[15] Hyder T,Nasrazadani A.Statins and endocrine resistance in breast cancer.Cancer Drug Resist2021;4:356-64 PMCID:PMC9019265

[16] Miller TW,González-Angulo AM.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.J Clin Invest2010;120:2406-13 PMCID:PMC2898598

[17] Bostner J,Pandiyan MJ.Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.Breast Cancer Res Treat2013;137:397-406 PMCID:PMC3539073

[18] Aleskandarany MA,Ahmed MA,Ellis IO.Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.Breast Cancer Res Treat2011;127:407-16

[19] Spears M,Taylor KJ.Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression.J Pathol2012;227:481-9

[20] Gudimchuk NB.Regulation of microtubule dynamics, mechanics and function through the growing tip.Nat Rev Mol Cell Biol2021;22:777-95

[21] Di Bartolomeo M,Cecchi F.Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.Tumori2021;107:150-9

[22] Duly AMP,Teo WS.βIII-tubulin gene regulation in health and disease.Front Cell Dev Biol2022;10:851542 PMCID:PMC9096907

[23] Kanakkanthara A.βIII-tubulin overexpression in cancer: causes, consequences, and potential therapies.Biochim Biophys Acta Rev Cancer2021;1876:188607

[24] Imran M,Chaudhuri A,Baboota S.Docetaxel: an update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer.J Drug Deliv Sci Technol2020;60:101959

[25] Raza F,You X,Wu J.Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers.J Mater Chem B2019;7:7639-55

[26] Yu Y.Optimizing particle size of docetaxel-loaded micelles for enhanced treatment of oral epidermoid carcinoma.Nanomedicine2016;12:1941-9

[27] Gao X,Huang Z.Reducing interstitial fluid pressure and inhibiting pulmonary metastasis of breast cancer by gelatin modified cationic lipid nanoparticles.ACS Appl Mater Interf2017;9:29457-68

[28] Iselt M,Hilgard P.The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity.Arzneimittelforschung1989;39:747-9

[29] Volkova YA,Komkov AV.Access to steroidal pyridazines via modified thiohydrazides.RSC Adv2016;6:42863-8

[30] Reid G,Métivier R.Cyclic, Proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling.Molecular Cell2003;11:695-707

[31] Scherbakov AM,Shatskaya VA,Gershtein ES.Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?.Breast Cancer Res Treat2006;100:1-11

[32] Mruk DD.Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits.Spermatogenesis2011;1:121-2 PMCID:PMC3271654

[33] Bogush TA,Saprykina NS.Experimental verification on the hypothesis about the possibility of molecular diagnostics of local tumor spread on the lewis lung carcinoma model.Moscow Univ Chem Bull2021;76:248-52

[34] Bergemann N,Parzer P.Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics.Schizophr Res2005;73:357-66

[35] Hassan LS,Danielson KK.Oestradiol levels may differ between premenopausal women, ages 18-50, with type 1 diabetes and matched controls.Diabetes Metab Res Rev2017;33:e2829 PMCID:PMC5124523

[36] Angsuwathana S,Rattanachaiyanont M.Serum follicle stimulating hormone and estradiol in peri/postmenopausal women attending Siriraj Menopause Clinic: a retrospective study.J Med Assoc Thai2006;89:1101-8

[37] Huitrón-Bravo G,Talavera JO.Levels of serum estradiol and lifestyle factors related with bone mineral density in premenopausal Mexican women: a cross-sectional analysis.BMC Musculoskelet Disord2016;17:437 PMCID:PMC5069822

[38] Nardulli AM,Carpo C,Rainish B.Estrogen receptor affinity and location of consensus and imperfect estrogen response elements influence transcription activation of simplified promoters.Mol Endocrinol1996;10:694-704

[39] Rato AG,Martinez MA,Lazo PS.Melatonin blocks the activation of estrogen receptor for DNA binding.FASEB J1999;13:857-68

[40] Bobin-Dubigeon C,Rossignol E,Amiand MB.New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.Future Sci OA2019;5:FSO374 PMCID:PMC6554689

[41] Woo HI,Kim J.Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.Oncotarget2017;8:100296-311 PMCID:PMC5725021

[42] Hassan F,El-hiti GA,Yousif E.Cytotoxic effects of tamoxifen in breast cancer cells.J Unexplored Med Data2018;3:3

[43] Kuznetsov YV,Scherbakov AM.New estrogen receptor antagonists. 3,20-Dihydroxy-19-norpregna-1, 3, 5(10)-trienes: synthesis, molecular modeling, and biological evaluation.Eur J Med Chem2018;143:670-82

[44] Seeger H,Wallwiener D.Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen.Horm Metab Res2004;36:277-80

[45] Brunsvig PF,Aamdal S,Olsen H.Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy.BMC Cancer2007;7:197

[46] Tsakalozou E,Bae Y.Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.Biochem Res Int2012;2012:832059 PMCID:PMC3395329

[47] Gupta S,Bearrs J.Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.Prostate Cancer Prostatic Dis2016;19:349-57 PMCID:PMC5133270

[48] Samadi N,Mohseni M.Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells.J Cancer Res Ther2014;10:715-21

[49] García-Becerra R,Díaz L.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Int J Mol Sci2012;14:108-45 PMCID:PMC3565254

[50] Ali S,Chaoudhry H.Molecular mechanisms and mode of tamoxifen resistance in breast cancer.Bioinformation2016;12:135-9 PMCID:PMC5267957

[51] Taylor SC,Yadav G.A defined methodology for reliable quantification of Western blot data.Mol Biotechnol2013;55:217-26 PMCID:PMC3840294

[52] Basappa B,Shinduvalli Kempasiddegowda M,Lobie PE.Novel biphenyl amines inhibit oestrogen receptor (ER)-α in ER-positive mammary carcinoma cells.Molecules2021;26:783 PMCID:PMC7913524

[53] Chavez KJ,Lipkowitz S.Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.Breast Dis2010;32:35-48 PMCID:PMC3532890

[54] Chaitanya GV,Babu PP.PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.Cell Commun Signal2010;8:31 PMCID:PMC3022541

[55] Amaral CL,Tamura RE.S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.BMC Cancer2016;16:602 PMCID:PMC4974797

[56] Sekino Y,Kawaguchi T.TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer.Int J Mol Sci2019;20:3936 PMCID:PMC6719236

[57] Razi Soofiyani S, Mohammad Hoseini A, Mohammadi A, Khaze Shahgoli V, Baradaran B, Hejazi MS. siRNA-mediated silencing of CIP2A enhances docetaxel activity against PC-3 prostate cancer cells.Adv Pharm Bull2017;7:637-43 PMCID:PMC5788219

[58] Razi Soofiyani S,Lotfipour F,Mohammadnejad L.Gene therapy, early promises, subsequent problems, and recent breakthroughs.Adv Pharm Bull2013;3:249-55 PMCID:PMC3848228

[59] Majidi Zolbanin N,Majidi J.Targeted Co-delivery of docetaxel and cMET siRNA for treatment of mucin1 overexpressing breast cancer cells.Adv Pharm Bull2018;8:383-93 PMCID:PMC6156474

[60] Sale MJ,Cook SJ.Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction.Cancer Drug Resist2019;2:365-80

[61] Cagnol S.ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence.FEBS J2010;277:2-21

[62] Subramaniam S.ERK and cell death: ERK1/2 in neuronal death.FEBS J2010;277:22-9

[63] Llorens F,Casañas A.Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death.Exp Cell Res2004;299:15-26

[64] Tang D,Hirao A.ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53.J Biol Chem2002;277:12710-7

[65] Chauvin L,Blanc C.Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways.Biochim Biophys Acta2016;1861:380-90

[66] Maahs L,Gupta N.Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer.PLoS One2019;14:e0222510 PMCID:PMC6816559

[67] De Donato M,Petrella L.Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.J Cell Physiol2012;227:1034-41

[68] Roque DM,Buza N.Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.Am J Obstet Gynecol2013;209:62.e1-9

[69] Saussede-Aim J,Ferlini C.Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.Cell Motil Cytoskeleton2009;66:378-88

[70] Terry S,Allory Y.Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.Br J Cancer2009;101:951-6 PMCID:PMC2743364

[71] Wright ME,Aebersold R.Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.Mol Endocrinol2003;17:1726-37

[72] Lebok P,Heilenkötter U.High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer.Oncol Lett2016;11:1987-94 PMCID:PMC4774425

[73] Pentheroudakis G,Kalogeras KT.Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.Breast Cancer Res Treat2011;127:179-93

[74] Hugh J,Cheang MC.Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.J Clin Oncol2009;27:1168-76